While some developers are implementing lessons learned - and launching - their 2nd C and GTs to market, the majority are hoping the launch strategy for their 1st holds strong, as they navigate through a meteor shower of risky unknowns, firsts, new partnerships, and complexities the average pharma team has never experienced before.
To succeed commercially, pharma and biotech need to formulate a launch strategy that engages the right commercial resource early on, rewrites traditional payment models in partnership with payers, and provides an integrated delivery network that scales up seamlessly, end-to-end.
At Reuters Events' Cell and Gene Therapy USA 2021, you will receive key lessons learned from those who have already achieved lift-off. C-suite, commercial strategy, manufacturing and supply, pricing and access experts will provide you with the tools to launch successfully and sustain and scale your cell and gene therapy delivery in to hyperdrive.
To succeed commercially, pharma and biotech need to formulate a launch strategy that engages the right commercial resource early on, rewrites traditional payment models in partnership with payers, and provides an integrated delivery network that scales up seamlessly, end-to-end.
At Reuters Events' Cell and Gene Therapy USA 2021, you will receive key lessons learned from those who have already achieved lift-off. C-suite, commercial strategy, manufacturing and supply, pricing and access experts will provide you with the tools to launch successfully and sustain and scale your cell and gene therapy delivery in to hyperdrive.
